Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It

Royalties Will Fuel R&D Expansion

Executive Summary

The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.

You may also be interested in...



Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants

Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available. 

Can JAK Inhibitors Save Lives From COVID-19? Pfizer Might Let RECOVERY Answer The Question

Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.

Blow For CureVac As COVID-19 Vaccine Hits 47% Efficacy

CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel